Climb Bio Inc (CLYM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $608.53M
Last updated: Nov 17, 2026 at 11:04 AM ET
Climb Bio Inc (CLYM) Competitors
The companies most similar to Climb Bio are Jade Biosciences (JBIO), Immix Biopharma (IMMX) and Cullinan Oncology LLC (CGEM). By market cap, Climb Bio ranks 7th of the 13 companies on this page; Jade Biosciences (JBIO) is the largest at $1.03B.
Peer Comparison
CLYM's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Climb Bio (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Jade Biosciences, Inc. (JBIO) | $1.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Orchestra BioMed Holdings Inc. (OBIO) | $570.61M | N/A | 14.7x | -182.5% | -97.0% | -89.4% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Annexon Inc (ANNX) | $747.79M | N/A | N/A | 0.0% | -84.6% | 0.0% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Peer median | $631.18M | N/A | 14.7x | 0.0% | -32.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Climb Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Jade Biosciences, Inc. (JBIO) | Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune... | JBIO competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Orchestra BioMed Holdings Inc. (OBIO) | Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. | OBIO competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Annexon Inc (ANNX) | Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. | ANNX competitors |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
Frequently Asked Questions About CLYM
Who are Climb Bio's main competitors?
The companies most similar to Climb Bio include Jade Biosciences (JBIO), Immix Biopharma (IMMX), Cullinan Oncology LLC (CGEM), Orchestra BioMed Holdings (OBIO) and Adlai Nortye Ltd. American Depositary Shares (ANL), listed from the closest match.
Who is Climb Bio's biggest competitor?
Jade Biosciences (JBIO) is both the largest of the similar companies at $1.03B and the closest match by business profile, size, sector and industry.
How does CLYM stock compare with its competitors?
CLYM's net margin is 0.0% against a peer median of 0.0%.
Which of Climb Bio's competitors pays a higher dividend?
Climb Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Climb Bio bigger than its competitors?
No. Climb Bio is 7th by market cap among the 13 companies on this page; the largest is Jade Biosciences (JBIO) at $1.03B.
CLYM pages: Overview, Earnings, Forecast, Financials, Competitors